‘Trojan horse' treatment given green light for NHS use
Blood cancer patients in England will be among the first in the world to have access to a new 'Trojan horse' treatment, health officials have announced.
The targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments, studies suggest.
It is estimated that around 1,500 patients a year with multiple myeloma – an incurable cancer of the bone marrow – will benefit from the treatment.
It comes after the National Institute for Health and Care Excellence (Nice) approved belantamab mafodotin, also known as Blenrep and made by GlaxoSmithKline, for NHS use.
NHS England said that it is the first health system in the world to roll out the treatment.
Officials said that the drug can now be offered to patients whose cancer has progressed or not responded to another first-line treatment.
The treatment, which is given as an infusion every three weeks along with other cancer drugs, is a type of antibody drug which targets and attaches to cancer cells.
It has been dubbed a 'Trojan horse' treatment because it works by being taken into a cancer cell, before releasing a high concentration of a lethal molecule to destroy the cell from inside.
'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' Professor Peter Johnson, NHS England's national clinical director for cancer, said.
'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family.
'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.'
🚨 Do you know the key symptoms of #myeloma? 🚨
Help us spread the word by sharing this post! Early diagnosis makes all the difference. If something feels off, don't wait – talk to your GP! #BloodCancerAwarenessMonth @MyelomaUK pic.twitter.com/8owed3w4Kn
— DKMS UK | We Delete Blood Cancer (@DKMS_uk) September 6, 2024
Helen Knight, director of medicines evaluation at Nice, said: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication.
'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.'
Trials have suggested that the treatment, in combination with bortezomib and dexamethasone, delayed progression of the disease by an average of three years, compared to just over a year for patients taking commonly-used drug daratumumab along with the other treatments.
Patient Paul Silvester, 60, from Sheffield, was diagnosed with myeloma in July 2023 and received treatment at the Royal Hallamshire Hospital.
The first treatment he was given failed to stop his cancer from progressing so he was given belantamab mafodotin through an early access programme.
'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said.
'It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future.
'I've been feeling well and I'm still quite active – that's what's important in terms of your quality of life.
'One of my daughters is graduating from university in October and it's a goal for me to be there.'
Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK, said: 'It's fantastic to see the UK at the forefront of myeloma treatment.
'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.'
Health Minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation.
'By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
Assura urged to reject bid from predator KKR
The battle for the future of GP surgery owner Assura escalated yesterday after a rival urged it to reject a bid from a private equity predator. Assura this week recommended that shareholders accept a sweetened £1.7billion bid from American buyout giant KKR and New York investment firm Stonepeak. The deal would see properties leased to the NHS, including doctors' surgeries, hospitals and hospices, fall into the hands of overseas owners. Most recently, Primary Health Properties (PHP) offered £1.68billion to buy Assura but it argued yesterday that its cash and stock bid is now worth more – as the value moves depending on share prices. And PHP dismissed Assura's claim that its offer posed 'material risks and downsides' for shareholders as it urged investors to take no action in relation to KKR's bid. A takeover by PHP would retain the properties under the ownership of a London-listed business. And it said Government spending plans for the NHS over the next three years would benefit both firms. KKR and PHP have been locked in a months-long tussle which has seen both parties up their offers several times since February to try to clinch a deal. The US private equity giant has made a 'best and final' cash offer of £1.7billion, up from its previous bid of £1.61billion. The bid of 52.1p per share includes two dividends: one which has already been paid and another that was declared last month. Russ Mould, investment director at broker AJ Bell, said: 'Shareholders in Assura now have the luxury of sitting back to watch what happens, in the view that some sort of deal seems certain.' Assura declined to comment.
The Guardian
5 hours ago
- The Guardian
Suman Fernando obituary
My friend and colleague Suman Fernando, who has died aged 92, had an international reputation in the field of critical psychiatry, particularly in relation to advocating for race equity in mental health. As well as being a consultant psychiatrist in the NHS for more than 20 years, Suman wrote 14 books and many articles in which he consistently and methodically challenged institutional racism in British mental health provision. In his first book, Race and Culture in Society (1988), he explored the role that race and culture play in how people experience mental health issues and services. In his breakthrough 1991 book, Mental Health, Race and Culture, he challenged the dominance and singularity of the medical model, and argued that any service response for minority communities should also focus on social, cultural and institutional issues. Suman often juxtaposed the western, individualised notion of mental illness with those of the global south or indigenous healing systems that see fragmentation of community cohesion as causal, with responses that are more spiritual and community-based. It is worth noting that the relatively recent inclusion of practices such as mindfulness and yoga into mental health recovery in the west are precisely those that have underpinned indigenous models for centuries. Born in Colombo in Ceylon (now Sri Lanka), Suman was the son of Charles, a doctor, and his wife, Esme (nee De Mel). He attended Royal college in Colombo, then followed in the footsteps of his father and grandfather, who had both studied medicine in the UK. Studying at Cambridge University and University College hospital in London, he qualified in 1958. After briefly returning to Ceylon to work in its only psychiatric hospital, on the outskirts of Colombo, he returned in 1960 to the UK, where the following year he married Frances Lefford, whom he had first met when they were students at University College hospital. Working as an NHS psychiatrist at Chase Farm hospital in Enfield, north London, he became a fellow of the Royal College of Psychiatrists in the early 1970s, and in 1975 received an MD from the University of Cambridge based on his studies in transcultural psychiatry. He retired in 1997. Suman remained deeply connected to his Sri Lankan heritage and supported many institutions and projects in the country, in particular the People's Rural Development Association, which he played a key role in establishing in 2007. He was also a partner in the Trauma and Global Health programme organised by McGill University in Montreal, Canada, which brought valuable mental health training to Sri Lanka. I first met Suman in Sri Lanka in the 90s, where we were both undertaking voluntary work. He was a kind, warm, humble and generous person who made time for everyone. He is survived by Frances, his daughter, Siri, two grandsons, Nathan and Alec, his brother Sunimal and sister Susila.
Daily Mail
6 hours ago
- Daily Mail
AMANDA PLATELL: It's not MY fault you're fat... so why should I pay for it?
Though the NHS is in crisis, with 7.4 million people still languishing on the waiting list for appointments and treatment, we are now told that fat-busting drugs such as Mounjaro will soon be as widely available as statins from your doctor, as accessible as a packet of Smarties for the overweight. Jolly good, but since nearly a third of the adult population are now considered obese there's one very big elephant in the room: the question of how much this will cost us taxpayers who do not happen to be fat.
